A study of more than 400,000 people found that fish oil supplements was associated with a 13 per cent heightened chance of developing atrial fibrillation
Regular use of fish oil supplements might increase, rather than lessen, the risk of first time heart disease and stroke among those in good cardiovascular health, but may slow progression of existing poor cardiovascular health and lower the risk of death, suggest the results of a large long term study, published in the open access journal BMJ Medicine.
Fish oil is a rich source of omega 3 fatty acids, and as such, is recommended as a dietary preventive to ward off the development of cardiovascular disease. But the evidence on how much protection it affords is inconclusive, explain the researchers.
To strengthen the evidence base, they set out to estimate the associations between fish oil supplements and new cases of atrial fibrillation; heart attack, stroke, and heart failure; and death from any cause in those with no known cardiovascular disease.
And they assessed the potential role of these supplements on the risk of progressing from good heart health (primary stage), to atrial fibrillation (secondary stage), to major cardiovascular events, such as a heart attack (tertiary stage), and death (end stage).
They drew on 415,737 UK Biobank study participants (55% women), aged 40-69, who were surveyed between 2006 and 2010 to gather basic background information. This included their usual dietary intake of oily and non-oily fish and fish oil supplements.
The participants’ health was tracked until the end of March 2021 or death, whichever came first, using medical records data.
Nearly a third (130,365; 31.5%) of the participants said they regularly used fish oil supplements. This group included higher proportions of older and White people, and women. Alcohol intake and the ratio of oily to non-oily fish eaten were also higher, while the proportions of current smokers and those living in deprived areas were lower.
During an average monitoring period of nearly 12 years, 18,367 participants developed atrial fibrillation, 22,636 had a heart attack/stroke or developed heart failure, and 22,140 died-;14,902 without atrial fibrillation or serious cardiovascular disease.
